Heart HealthJuly 23, 2026·4 min read
By the CIRRUS Editorial Team — how we write and source this
GLP-1 drugs and kidney protection: what the FLOW trial found
Semaglutide's kidney-outcomes trial in type 2 diabetes with chronic kidney disease stopped early — for the right reason.
The FLOW trial studied semaglutide specifically in patients with type 2 diabetes and chronic kidney disease, tracking kidney function decline, kidney failure, and cardiovascular death as primary outcomes. An independent monitoring committee recommended stopping the trial early after an interim analysis showed a clear reduction in major kidney disease events — enough of a signal that continuing the placebo arm was no longer considered appropriate.
This matters beyond the diabetes population specifically studied: chronic kidney disease frequently coexists with obesity, hypertension, and sleep apnea, and a drug class already prescribed for weight management showing a direct renal-protective signal changes the risk-benefit calculation for patients managing multiple conditions simultaneously.
It's not a reason to self-prescribe GLP-1 therapy for kidney protection alone — the trial population had both diabetes and CKD, and eligibility, dosing, and monitoring were specific to that population. It is a reason to raise the trial with a nephrologist or endocrinologist if you're managing CKD and haven't discussed GLP-1 therapy.
This article is general health information, not medical advice, and doesn’t replace evaluation by your own physician. Talk to a doctor about anything specific to your own diagnosis or treatment.